Why Semaglutide Isn’t Working for You: 8 Real Reasons
At Rivas, we often find that patients who have previously bought semaglutide online have not received optimal outcomes due to several key factors.
- Most cases of “semaglutide not working” are actually dosing or titration issues
- Nearly half of GLP-1 patients stop at 180 days due to side effects (52%), supply issues (33%), and cost (25%)
- A 2025 study found patients seeing an obesity specialist were 8 times more likely to stick with GLP-1s
- Rivas Medical Weight Loss has been treating obesity since 1991. Our providers see GLP-1 response patterns every week across 15 locations in MD, VA, and FL.
Semaglutide works for most patients when prescribed at the right dose, titrated correctly, and supported by clinical care that catches problems early. When semaglutide appears to “not work,” the issue is almost never the medication. It’s usually dose, titration speed, expectation mismatch, an unrecognized plateau, or care that isn’t built for obesity medicine. Read the rest of this post so you can know how to tell the difference.
Reason No. 1: Your dose may be too low
The single most common reason semaglutide appears to stop working is that the patient is sitting at a sub-therapeutic dose for too long.
Semaglutide for weight loss starts at 0.25 mg weekly. That dose is for tolerability, not weight loss. Clinically meaningful appetite suppression and weight loss typically don’t appear until 1.0 mg or higher. The full Wegovy escalation runs through 2.4 mg, and as of March 2026, an FDA-approved higher dose of 7.2 mg is now available (Wegovy HD).
If you’ve been at 0.25 mg or 0.5 mg for more than two months and aren’t seeing results, that’s expected. You’re on the dose meant to get your body used to the drug, not the dose meant to drive weight loss.
What to look for: A prescriber who is comfortable escalating, who tracks your response weekly or monthly, and who doesn’t keep you at a starter dose for fear of side effects when you’re tolerating it fine.
Learn more: Check out our GLP-1 Dose Calculator
Reason No. 2: Your titration (dose increase) was too fast
The opposite problem is also common. Some prescribers move patients up the dose ladder too quickly, often to get to “the dose that’s supposed to work.” This usually causes side effects severe enough that the patient either stops the medication or has to drop back down.
Aggressive titration is one of the leading reasons patients stop using GLP-1s. In a 2025 study published in Obesity Medicine, 52% of patients who discontinued GLP-1 therapy cited adverse effects as the main reason.
The clinical principle is “start low and go slow.” Your dose should escalate based on how you are tolerating it, not on a manufacturer’s pre-set schedule.
What to look for: A prescriber who asks how you’re tolerating the current dose before escalating, not one who escalates by default at every visit.
Reason No. 3: You ARE losing weight. The scale is lying.
This one surprises patients. They feel like the medication isn’t working because the scale hasn’t moved much. But when we measure body composition, they’ve lost significant fat and gained or held muscle.
The scale measures everything: water, glycogen, food in transit, muscle, fat. Weekly fluctuations of 2-to-4 pounds in either direction are normal. If you’re tracking by scale weight alone, you may be missing real progress.
“One of my patients came in at 12 weeks convinced the medication wasn’t working,” says Ashley DeLashmutt PA-C, a Rivas provider. “She’d lost 18 pounds and couldn’t see it. I asked her to take side-by-side photos. She came back the next week and said, ‘Oh my God, I can’t believe how much I’ve changed.’ She stayed on the plan for 18 months and lost 80 pounds. She just needed something tangible to measure change by.”
What to look for: Body composition tracking, not just the scale. Photos, measurements, how your clothes fit, and how you feel are all data.
Learn more about how to gauge your body composition changes and what else you can do to improve it
Reason No. 4: You’re in a plateau, not a failure
Plateaus happen. The body adapts to weight loss by lowering resting metabolic rate, increasing appetite-stimulating hormones, and conserving energy. This is normal physiology, not the medication failing.
Most GLP-1 patients hit at least one plateau in their treatment course. The clinical question is what to do about it: dose adjustment, titration change, lifestyle review, or sometimes a switch to a different molecule.
What to look for: A prescriber who recognizes plateaus as a clinical event, not a personal failure. Plateaus are managed, not waited out.
Have you hit a Wegovy or Ozempic Plateau? Here’s what’s happening
Reason No. 5: You’re losing muscle along with fat
When weight loss is rapid, the body sheds both fat and muscle. Research suggests 25-to-39 percent of weight lost on GLP-1s is fat-free mass, mostly muscle (Lieberman et al., JAMA 2026). Muscle loss lowers your resting metabolism, which can slow further weight loss.
Patients who don’t account for this often hit a “plateau” that’s really just a metabolism adjusting to a lower muscle mass.
The fix is protein, resistance training, and clinical attention to body composition rather than scale weight alone.
What to look for: A prescriber who talks to you about protein intake (1.2 to 1.6 g/kg/day is the consensus target for GLP-1 patients), resistance training, and body composition.
Learn more: Check out our GLP-1 Protein and Water Calculator
Reason No. 6: Your prescriber may not be experienced with obesity medicine
A 2025 cross-sectional study published in Obesity Medicine found that patients treated by an obesity specialist were 8 times more likely to remain on GLP-1 therapy than patients treated in general care settings (Liu et al., 2025).
This is not a knock on primary care. Primary care physicians manage 20 conditions in 15-minute appointments. Obesity medicine requires a different cadence: titration tuning, side-effect management, nutritional support, body composition tracking, and a long-term relationship with the patient. That’s hard to deliver in standard PCP visits.
The same study found that the most common reasons patients stop GLP-1 therapy are adverse effects (52%), medication shortages (33%), and cost (25%). Every one of those is something an experienced obesity medicine practice is built to navigate.
What to look for: A practice that specializes in obesity medicine, sees you weekly or monthly (not annually), and has a track record of managing long-term GLP-1 care.
Reason No. 7: Your lifestyle is fighting the medication
Semaglutide reduces appetite but it does not change what you eat when you do eat.
Patients who lose the most weight on GLP-1s tend to make protein-forward food choices, stay hydrated (GLP-1s slow gastric emptying and dehydrate patients faster than they realize), prioritize sleep (sleep deprivation drives weight regain), and add some form of strength training.
If you’re eating ultra-processed food in smaller quantities, dehydrated, and sleeping poorly, the medication is still working as designed. It’s the surrounding behavior that’s blunting results.
What to look for: A provider who actually talks to you about protein, water, sleep, and movement, not just dose.
Reason No. 8: The semaglutide product itself may not be the right fit
Semaglutide is one specific molecule. Tirzepatide is a different molecule (a dual GIP/GLP-1 agonist) that produces greater average weight loss in head-to-head trials. In SURMOUNT-5 (NEJM 2025), tirzepatide produced 20.2% average weight loss vs. 13.7% for semaglutide over 72 weeks.
For some patients, semaglutide will simply not produce the level of response they need. Tirzepatide (sold as Zepbound for weight loss, Mounjaro for diabetes) is often the next clinical step.
What to look for: A practice that prescribes the full range of GLP-1 medications, including tirzepatide, and can move you between them when clinically appropriate.
What ongoing care actually looks like
If you’re on semaglutide and not seeing results, the answer is rarely “give up” or “try harder.” The answer is usually a clinical conversation about which of the eight reasons above applies to you.
At Rivas, that conversation is the entire first visit. We look at your dose, your titration history, your current body composition, your protein and hydration, your sleep, your stress, and your goals. Then we build a plan. Many of our patients end up combining semaglutide care with body composition support, nutritional planning, or a switch to tirzepatide when clinically appropriate.
A medication this powerful deserves a practice that takes it seriously.
Considering a second opinion on your semaglutide treatment?
Rivas has been a physician-led obesity medicine practice since 1991. Our providers see GLP-1 patients every week across 15 locations in Maryland, Virginia, and Florida. The consultation is complimentary.
HSA & FSA accepted · Financing available
To learn more about semaglutide, check out these articles:
- Weekly semaglutide dosing chart
- The Wegovy Pill: A Needle-Free GLP-1 Weight Loss Option
- Can you cut the Wegovy pill in half?
- Semaglutide Side Effects: Common vs. Serious
- Semaglutide: A Game-Changer in Weight Loss and Type 2 Diabetes Management
- Semaglutide Vs Phentermine
- Semaglutide vs. Liraglutide
- What does Semaglutide do to the body?
- How fast does semaglutide work?
FAQs
Most patients notice appetite changes within the first one to two weeks. Clinically meaningful weight loss typically appears between 8 and 12 weeks of treatment, often coinciding with reaching higher therapeutic doses (1.0 mg or above).
The most common reason is that the patient is on a sub-therapeutic dose for too long. The starter dose of 0.25 mg is for tolerability, not weight loss. Clinically meaningful response usually begins at 1.0 mg or higher.
Some patients respond less than expected even at therapeutic doses. In those cases, tirzepatide (a dual GIP/GLP-1 agonist) often produces better results. The two drugs have distinct mechanisms, so tolerance or response to one does not predict tolerance or response to the other.
A 2025 study published in Obesity Medicine found that patients treated by an obesity specialist were 8 times more likely to persist on GLP-1 therapy than those treated in general care settings. The most common reasons patients discontinue (adverse effects, supply issues, cost) are challenges an experienced obesity medicine practice is built to navigate.
That’s a clinical decision with your provider. In head-to-head trials (SURMOUNT-5), tirzepatide produced greater weight loss than semaglutide. But cost, tolerability, side-effect profiles, and individual response all factor in.
Compounded semaglutide is not the same as FDA-approved Wegovy. Compounded medications are prepared by licensed pharmacies and are not FDA-approved finished drug products. At Rivas, we may prescribe either compounded semaglutide or brand-name Wegovy depending on the clinical situation. Both are administered under provider supervision.
Citations
1. Liu S, et al. Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study. Obesity Medicine. 2025.
2. Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026.
3. Khan SS, Ndumele CE, Kazi DS. Discontinuation of glucagon-like peptide-1 receptor agonists. JAMA. 2025.
4. Aronne LJ, et al. SURMOUNT-5 trial. NEJM. 2025.
5. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. ACLM/ASN/OMA/TOS Joint Advisory. AJCN. 2025.
